Injecting stem cells to heal Crohn's disease lesions

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the efficacy and safety of local injections of mesenchymal stromal cells (MSC) in patients with Crohn's disease who have refractory intestinal and perianal lesions. The study will include patients aged 18 and older who have had Crohn's disease for more than six months and have lesions that have not responded to conventional and biologic therapies. The trial will assess the healing of these lesions and monitor any potential safety concerns associated with the treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients ≥ 18 years of age
* Signing the informed consent
* Diagnosis of Crohn Disease for more than 6 months
* Presence of at least one Crohn Disease lesion refractory to conventional therapies (azathioprine, 6-mercaptopurine or methotrexate) and to biologic treatments (anti-Tumor Necrosis Factor therapies, vedolizumab, or ustekinumab).
* Refractory lesion defined by (1) a stricture with a length of 2 to 5cm of the colon or the ileum accessible by ileocolonoscopy (i.e. a lesion identified during a colonoscopy with a lumen narrowing non passable by the colonoscope), (2) unhealed deep ulcer of the colon or the ileum accessible to ileocolonoscopy, or (3) actively draining perianal fistula(s).
* Twenty patients with stricture(s), 20 patients with unhealed deep ulcer(s), and 20 patients with an actively draining perianal fistula(s) will be included

Exclusion Criteria:

* Indication for immediate luminal surgery
* Intestinal obstruction
* Intra-abdominal fistulas or abscess
* Intestinal/colonic stricture or deep unhealed ulcer not accessible to ileocolonoscopy
* Undrained peri-anal abscess
* Pregnant women or planning pregnancy within one year
* Positive stool culture/toxin for clostridium difficile pathogen or other pathogens
* Renal failure (anuria, serious fluid overload, Glomerular Filtration Rate \< 30 ml/min, dialysis) or hepatic failure (Fulminant liver failure, cirrhosis of the liver with evidence of portal hypertension, alcoholic hepatitis, esophageal varices, a history of bleeding esophageal varices, hepatic encephalopathy, uncorrectable hepatic synthetic dysfunction evinced by prolongation of the prothrombin time, ascites related to portal hypertension, bacterial or fungal liver abscess, biliary obstruction, chronic viral hepatitis with total serum bilirubin \>3 mg/dL)
* documented human immunodeficiency virus infection; active hepatitis B, C, or tuberculosis
* an opportunistic infection within 6 months before screening or a serious infection in the previous 3 months
* malignancy within the past 5 years; or a history of lymphoproliferative disease

Where it's running

• CHU de Liège
  Liège, Liège, Belgium Recruiting

Study contacts

• Principal investigator: Edouard Louis, Prof — Centre Hospitalier Universitaire de Liege
• Study coordinator: Edouard Louis, Prof
• Email: edouard.louis@uliege.be
• Phone: 043667256

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Stent-assisted Coil Embolization for Acute Ruptured Intracranial Aneurysms

  This study tests whether stent-assisted coil embolization for ruptured intracranial aneurysms can be safely used in the acute period and help prevent rebleeding.

  Recruiting Tang-Du Hospital · Xi'an, Shaanxi · NCT07683377

• Thermal ablation plus antithyroid medication for primary hyperthyroidism

  This trial tests whether adding thermal ablation to antithyroid drugs helps people with primary hyperthyroidism get faster symptom relief and fewer complications long term.

  Recruiting Chinese PLA General Hospital · Beijing · NCT07557810

• Biologic treatment for adults with ABPA and severe asthma

  This project will test whether biologic medicines help adults with ABPA who have severe asthma and elevated eosinophils.

  Recruiting Qianfoshan Hospital · Jinan, Shandong · NCT07362693

• Comparing a finger splint, paraffin baths, and peloidotherapy for trigger finger

  This tests whether a finger splint, paraffin baths, or peloidotherapy works best to reduce pain and catching in adults 18–75 with a single trigger finger.

  Recruiting Konya Beyhekim Training and Research Hospital · Konya, Konya · NCT07256522

• Comparing two types of radiation therapy for breast cancer

  This study is testing whether a new type of radiation therapy for breast cancer is safer and more effective than the standard treatment to help patients feel better and live longer.

  Recruiting Ruijin Hospital · Shanghai, Shanghai Municipality · NCT06826885

• Combining Fuzuloparib and Arsenic Trioxide for Ovarian Cancer Treatment

  This study is testing a new combination of two drugs, Fuzuloparib and Arsenic trioxide, to see if it can help people with ovarian cancer who haven't responded to other treatments.

  Recruiting Phase 1/2 Women's Hospital School Of Medicine Zhejiang University · Zhejiang, Hangzhou · NCT04518501

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.